Tag:

interferon

Latest Headlines

Latest Headlines

Just as hep C star Sovaldi makes its debut, Gilead commercial chief says he'll retire

Gilead Sciences just rolled out its much-anticipated hepatitis C treatment Sovaldi (sofosbuvir) last month. Now, the company's commercial chief is saying sayonara. EVP Kevin Young will retire Feb. 4, leaving his team to soldier on alone with the Sovaldi launch.

Roche, billionaire-backed biotech partner on hep C drug in China

Roche and the biotech startup Ascletis have joined forces to advance Roche's experimental drug danoprevir for hepatitis C virus in for the Chinese market.

Nuron Biotech bags $80M deal to back vaccines portfolio, PhIII MS drug work

The investment cash has been flowing into biotechnology this week. This morning Nuron Biotech joined the parade, announcing an $80 million deal designed to boost its work expanding a portfolio of vaccines while pushing ahead on a late-stage development program for multiple sclerosis.

Glaxo nabs FDA approval for hep C remedy Promacta

GlaxoSmithKline has won an FDA approval to market Promacta to hepatitis C patients whose low blood platelet counts prevent them from taking interferon, a commonly used treatment linked to a host of side effects.

Hep C pill race report 2012: Gilead, others rush toward pharma gold

The evolution of hepatitis C treatment threatens to leave today's dominant companies with fossilized offerings. Vertex and Merck have the state-of-the-art approved drugs against the virus, but both companies are chasing after Gilead Sciences, Abbott Laboratories and others with programs that could be the first to win market approval with pill-only options.  Read the full report >>

Sanofi's Lemtrada beats Rebif in head-to-head showdown

Sanofi's Genzyme group in Boston put up a new set of data to back its bid to make Lemtrada a leading therapy for multiple sclerosis.

Abbott's hep C combo aces latest test

Abbott Laboratories ($ABT) made a late entry into the red-hot race to develop an interferon-free approach to hepatitis C.

Defining 'fierce' in the modern age of drug and device development

Now, more than ever, the life sciences industry is all about innovative and disruptive technologies. Every year for the past decade, FierceBiotech has made its picks on which companies hold the best odds for success in our Fierce 15 report. This year, though, we've added another Fierce 15 to focus on medical devices and diagnostics. I'd like to encourage readers to consider the differences by comparing the companies in each report.

Vertex dumps one hep C dud, races ahead with second all-oral hope

A little more than a year after Vertex licensed in a pair of "nucs" from Alios BioPharma in a high-stakes bid to develop an oral, interferon-free approach to hepatitis C, Vertex is jettisoning one as a dud while racing ahead with the second into a mid-stage study slated to begin in a matter of weeks.

FierceBiotech's 2012 Fierce 15 at BioPharm America

Nick Leschly, the CEO of Bluebird Bio, playfully dubbed the ambitious spirit of biotechs Levin Syndrome, a fictional affliction named after Third Rock Ventures' Mark Levin that compels biotech entrepreneurs to, as they say, go big or go home. Our Fierce 15 companies are all "going big." They also went home… with trophies. Check out the slideshow below.